Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Malignant Pleural Effusion
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: imatinib mesylate
Drug: paclitaxel

First Posted Date: 2006-12-07

Last Posted Date: 2017-04-25

Lead Sponsor: University of Washington

Target Recruit Count: 34

Registration Number: NCT00408460

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Ovarian Sarcoma
Ovarian Stromal Cancer
Recurrent Endometrial Carcinoma
Recurrent Ovarian Epithelial Cancer
Recurrent Ovarian Germ Cell Tumor
Stage III Endometrial Carcinoma
Stage III Ovarian Epithelial Cancer
Stage III Ovarian Germ Cell Tumor
Stage IV Endometrial Carcinoma
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: temsirolimus

First Posted Date: 2006-12-07

Last Posted Date: 2014-06-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT00408655

Locations: 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 2

Terminated

Conditions: Peritoneal Cancer
Fallopian Tube Cancer
Stage 3 Cancer
Stage 4 Cancer
Ovarian Cancer

Interventions: Drug: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-12-06

Last Posted Date: 2018-03-08

Lead Sponsor: UConn Health

Target Recruit Count: 5

Registration Number: NCT00408070

Locations: 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2006-11-23

Last Posted Date: 2019-02-20

Lead Sponsor: George Albert Fisher

Target Recruit Count: 31

Registration Number: NCT00403130

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2006-11-20

Last Posted Date: 2016-01-14

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 26

Registration Number: NCT00401674

Locations: 🇮🇹
Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy
🇮🇹
Ospedale S. Giovanni Calibita Fatebenefratelli, Roma, Italy
🇮🇹
Università Cattolica del Sacro Cuore, Dipartimento di Oncologia, Campobasso, CB, Italy

and more 7 locations

Phase I Trial of Paclitaxel With Perifosine

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2006-11-14

Last Posted Date: 2014-02-13

Lead Sponsor: AEterna Zentaris

Target Recruit Count: 24

Registration Number: NCT00399126

Locations: 🇺🇸
AOI Pharmaceuticals Investigative Site, Johnson City, Tennessee, United States

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Adriamycin and Cytoxan (AC)
Drug: ABI-007
Drug: Taxol
Drug: Bevacizumab
Drug: pegfilgrastim

First Posted Date: 2006-10-31

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 197

Registration Number: NCT00394251

Treatment of Head & Neck Cancer With Chemotherapy and Radiation

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Bevacizumab
Drug: Erlotinib
Drug: Paclitaxel
Drug: 5-FU
Radiation: Radiation Therapy

First Posted Date: 2006-10-26

Last Posted Date: 2013-02-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 60

Registration Number: NCT00392704

Locations: 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States

and more 4 locations

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Erlotinib
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: 5-FU
Procedure: Radiation therapy
Procedure: Surgery

First Posted Date: 2006-10-26

Last Posted Date: 2022-03-02

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 62

Registration Number: NCT00393068

Locations: 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 6 locations

Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Neoplasms
Peritoneal Neoplasm

Interventions: Drug: carboplatin
Drug: enzastaurin
Drug: placebo
Drug: paclitaxel

First Posted Date: 2006-10-23

Last Posted Date: 2020-10-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 153

Registration Number: NCT00391118

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy